HIV/AIDS Clinical Trial
— CohMSM-PrEPOfficial title:
Access to Pre-exposure Prophylaxis for Men Who Have Sex With Men: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)
Verified date | January 2024 |
Source | ANRS, Emerging Infectious Diseases |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This demonstration project will assess the acceptability and feasibility of pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) as part of a comprehensive HIV prevention package in community-based clinics in West Africa. An interventional, open label, multidisciplinary and multicentre cohort study will be performed in Burkina Faso, Côte d'Ivoire, Mali, and Togo. All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (daily or on-demand, according the participant's choice), immunisation against hepatitis B, individualised peer-led support (for adherence and prevention), group discussions, condoms, and lubricants.
Status | Completed |
Enrollment | 649 |
Est. completion date | June 30, 2021 |
Est. primary completion date | December 23, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male (or transgender male person at birth) - At least 18 years old - HIV-seronegative - Having had at least one anal sex episode with another man within the previous 6 months - Having at least one of the following criteria: - Have a sexual partner (male or female) infected with HIV without evidence of virological suppression - Have had anal or vaginal sex episodes without condoms with more than one partner within the previous 6 months - Have had a sexually-transmitted infection (STI) within the previous 6 months (syndromic or biological approach, or mentioned by the participant) - Have received post-exposure prophylaxis for HIV within the previous 6 months - Wishing to reinforce its means of prevention through the use of PrEP - Accepting to participate in the study and signing the informed consent form Exclusion Criteria: - Clinical manifestations suggesting a primary HIV infection - Recent probable HIV exposure - Creatinine clearance <60 mL/min calculated according to the Cockroft & Gault formula - Positive or undetermined HBsAg - Allergy or contraindication to any of the components of PrEP - Participation in another biomedical and/or behavioral study on HIV or STIs (excluding CohMSM) - Disability of the person making it difficult, if not impossible, to participate in the study or understanding of the information given to him - Predictable non-compliance with the protocol (geographical distance, non-compliance with monitoring or other reasons) |
Country | Name | City | State |
---|---|---|---|
Burkina Faso | Centre Oasis, Association African Solidarité | Ouagadougou | |
Côte D'Ivoire | Clinique de Confiance, Espace Confiance | Abidjan | |
Mali | Clinique des Halles, ARCAD-SIDA | Bamako | |
Togo | Centre Lucia, Espoir Vie Togo | Lomé |
Lead Sponsor | Collaborator |
---|---|
ANRS, Emerging Infectious Diseases | ARCAD-SIDA MALI, Association African Solidarité, Centre de Recherche Internationale pour la Santé, Université de Ouagadougou, Coalition Internationale Sida, Espace Confiance, Côte d'Ivoire, Espoir Vie-Togo - ONG, Expertise France, Institut de Médecine Tropicale, Anvers, Belgique, Laboratoire BIOLIM, Université de Lomé, SESSTIM (IRD, Inserm, Université Aix-Marseille), Université Montpellier |
Burkina Faso, Côte D'Ivoire, Mali, Togo,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of MSM under PrEP among eligible HIV-seronegative participants | To assess the acceptability of PrEP | 3 years | |
Primary | Percentage of MSM using daily and/ord on-demand PrEP | To assess the acceptability of PrEP | 3 years | |
Primary | Number of MSM followed after 3 years compared to the number of MSM included (retention in the program) | To assess the acceptability of PrEP | 3 years | |
Primary | Percentage of adherence reported by MSM | To assess the adherence to PrEP | 3 years | |
Primary | Counting of TDF/FTC tablets | To assess the adherence to PrEP | 3 years | |
Primary | Plasma concentrations of TDF and FTC | To assess the adherence to PrEP | 3 years | |
Primary | Percentage of HIV tests performed | To assess the adherence to quarterly HIV testing | 3 years | |
Primary | Clinical and biological adverse events related to TDF and FTC | To assess the safety of daily and on-demand use of TDF/FTC | 3 years | |
Primary | Frequency of condomless anal intercourse | To assess the evolution of the other prevention strategies on PrEP | 3 years | |
Primary | Frequency of sexual intercourse associated with alcohol and/or drug use | To assess the evolution of the other prevention strategies on PrEP | 3 years | |
Primary | Incidence rate of STIs | To assess the incidence of STIs on PrEP | 3 years | |
Primary | Incidence rate of HIV infection | To assess the "real life" effectiveness of PrEP use and the emergence of treatment-related resistance | 3 years | |
Primary | Percentage of TDF/FTC resistance among MSM newly infected by HIV | To assess the "real life" effectiveness of PrEP use and the emergence of treatment-related resistance | 3 years | |
Primary | Total cost of the intervention over the study period and in the long term | To assess the cost and cost-effectiveness of PrEP | 3 years | |
Primary | Incremental cost-effectiveness ratio of the intervention (versus no intervention) over the study period and in the long term | To assess the cost and cost-effectiveness of PrEP | 3 years | |
Primary | Conditions of TDF/FTC price and of effectiveness for the intervention to be cost-effective in the study countries | To assess the cost and cost-effectiveness of PrEP | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03289676 -
Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV
|
Phase 1 | |
Completed |
NCT03215901 -
Life Plans Intervention Study
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Active, not recruiting |
NCT04064567 -
Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK
|
N/A | |
Completed |
NCT04013295 -
Prize-linked Savings Initiatives for Promoting Better Health and Economic Outcomes in Kenya
|
N/A | |
Recruiting |
NCT04405700 -
Measuring Adverse Pregnancy and Newborn Congenital Outcomes
|
||
Recruiting |
NCT03984136 -
HIV Results Exchange Mechanism on Promoting HIV Testing Among MSM
|
N/A | |
Completed |
NCT02928900 -
Patient Actor Training to Improve HIV Services for Adolescents in Kenya
|
N/A | |
Recruiting |
NCT03268109 -
COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
|
||
Completed |
NCT02797262 -
Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System
|
N/A | |
Completed |
NCT02376582 -
Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS
|
Phase 1 | |
Completed |
NCT01957865 -
Real-Time Antiretroviral Therapy Adherence Intervention in Uganda
|
N/A | |
Completed |
NCT01616940 -
Minority AIDS Initiative Retention and Re-Engagement Project
|
N/A | |
Terminated |
NCT01443923 -
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
|
Phase 4 | |
Completed |
NCT01910714 -
Adapting and Evaluating an EBI to Prevent HIV/AIDS Risk Among Apache Youth
|
N/A | |
Completed |
NCT01084421 -
A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos
|
N/A | |
Completed |
NCT01596322 -
International HIV Antiretroviral Adherence, Resistance and Survival
|
N/A | |
Completed |
NCT03643705 -
A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention
|
N/A | |
Completed |
NCT03923231 -
Pharmacokinetics of Atazanavir in Special Populations
|